Consumer Health Services

Integrated Consumer Engagement and Support Solutions

Complete, compliant solutions for today's evolving Consumer Health landscape.

ProPhama's Consumer Health Services

Consumer Health Services provide compliant, end-to-end support across consumer engagement, safety monitoring, and quality processes. Expertise spans diverse product portfolios and global markets, ensuring accurate information delivery, consistent consumer experiences, and alignment with regulatory requirements.

Woman shopping at store with smartphone
Braining storming at a business meeting

Our Approach

An Integrated Consumer Health Model

An integrated Consumer Health model supports engagement across multiple touchpoints, including the management of consumer inquiries, proactive identification of Adverse Events and Product Quality Complaints, and timely documentation and reporting in accordance with regulatory requirements. Engagement, safety monitoring, and quality processes are connected to support a consistent, compliant, and consumer-centric experience while safeguarding critical product and patient information.

Structured support solutions strengthen compliance, operational consistency, and risk management across the Consumer Health Service line. Established procedures and controlled processes support data integrity, audit readiness, and regulatory expectations, while enabling accurate identification, documentation, and reporting of safety and quality information within required timelines.

Consumer Health Capabilities

Consumer Health & Information Delivery
Patient support programs icon

Customized Consumer Health Solutions

Tailored service programs designed to your specific needs across diverse product portfolios. These solutions are strategically configured to meet therapeutic area...

Read More

Customized Consumer Health Solutions

Tailored service programs designed to your specific needs across diverse product portfolios. These solutions are strategically configured to meet therapeutic area requirements and product classifications, such as Over-the-Counter (OTC), Nutritional, Cosmeceutical, and Prescription products. Our dedicated call center operations and Consumer Health teams provide expert support by delivering on-label information sourced from approved FAQs and regulatory resources, ensuring consistent and compliant support for both healthcare professionals and consumer inquiries.

Read Less
Decentralized Clinical Trials icon

Over-the-Counter and Retail Product Services

ProPharma direct-to-consumer Consumer Health Services for OTC products has become your primary connection point with end users, delivering the exceptional...

Read More

Over-the-Counter and Retail Product Services

ProPharma direct-to-consumer Consumer Health Services for OTC products has become your primary connection point with end users, delivering the exceptional service quality that drives brand loyalty and repeat purchases.

Read Less
Entrepreneurial

Community Management Capabilities

Modern Consumer Health Services leverage digital platforms to monitor sponsored content and influence partnerships across a range of digital and social media...

Read More

Community Management Capabilities

Modern Consumer Health Services leverage digital platforms to monitor sponsored content and influence partnerships across a range of digital and social media environments.

  • Standardized medical information responses delivered in alignment with approved product labeling and FAQs.
  • Social media and ecommerce monitoring
  • Trend Analysis Reports
Read Less
Pharmacovigilance

Safety & Quality Oversight

Highly Qualified Experts

Consumer Health Services serve as the critical first point of contact for Adverse Events and Product Quality Complaints reporting. Our trained specialists conduct thorough assessments to capture complete Adverse Event and Product Quality Complaint information. Consumer Health Services manage end-to-end quality complaint processes, from documentation through quality assurance coordination and consumer updates.

Global contact center support icon

Consumer Access & Support Programs

Product Reimbursement, Replacement Programs & Financial Assistance

Consumer Health Services provide specialized reimbursement and replacement support.

  • Facilitation of physical and digital coupon distribution.
  • Financial assistance and Co-Pay programs.
  • Sample retrieval services manage specialized logistics including prepaid shipping, proper packaging, and chain of custody
Around the world icon

Global Delivery & Operational Excellence

Multilingual Services

Support available in 35+ languages to serve diverse consumer populations globally.

Contact a Consumer Health Expert

We are committed to supporting consumer safety and experience through our competitive Consumer Health Services. Whether you require robust monitoring of digital and social channels or a full-service approach including engagement and response management, our team of experts is equipped to ensure timely, accurate, and compliant handling of all consumer interactions.

News & Insights

Understanding For-Cause Audits: A GMP Case Study

May 11, 2026

Understanding For-Cause Audits: A GMP Case Study

Explore the critical role of for-cause audits in GMP environments, uncovering how minor discrepancies can reveal systemic risks and enhance quality oversight.qua

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strategy

May 5, 2026

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strat...

Preparing for an IND submission? Discover 12 critical questions sponsors should answer to reduce FDA risk, avoid delays, and strengthen submission readiness.

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity Expectations

April 30, 2026

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity ...

Recent cyberattacks on MedTech leaders highlight growing regulatory and patient safety risks. Explore key lessons and how FDA cybersecurity guidance is shaping compliance and resilience.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Whitepapers IND Readiness Checklist: Assess Your FDA Submission Risk

May 4, 2026

IND Readiness Diagnostic: 12 Questions Sponsors Should Answer Before Submitting

A Practical Framework to Assess IND Readiness Before Filing Identify gaps early. Reduce FDA risk. Strengthen your submission strategy. Preparing for an Investigational New Drug (IND) submission...

Case Study Reducing Patient Burden While Maintaining High-Frequency  Monitoring in a Hemophilia Gene  Therapy Trial

April 20, 2026

Reducing Patient Burden While Maintaining High-Frequency Monitoring in a Hemoph...

Balancing rigorous clinical oversight with patient accessibility is critical in complex gene therapy trials. Intensive early-phase monitoring and complex protocols can place significant burden on...

Case Study Ensure Launch Readiness—Even on the Tightest Timelines

March 30, 2026

Ensure Launch Readiness, Even on the Tightest Timelines

Expediting Promotional Review to Deliver 60+ Materials in Just 4 Weeks When timelines are compressed and stakes are high, promotional review processes can quickly become a bottleneck. This case study...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

News & Insights

Understanding For-Cause Audits: A GMP Case Study

May 11, 2026

Understanding For-Cause Audits: A GMP Case Study

Explore the critical role of for-cause audits in GMP environments, uncovering how minor discrepancies can reveal systemic risks and enhance quality oversight.qua

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strategy

May 5, 2026

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strat...

Preparing for an IND submission? Discover 12 critical questions sponsors should answer to reduce FDA risk, avoid delays, and strengthen submission readiness.

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity Expectations

April 30, 2026

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity ...

Recent cyberattacks on MedTech leaders highlight growing regulatory and patient safety risks. Explore key lessons and how FDA cybersecurity guidance is shaping compliance and resilience.

Previous Post Arrow Next Post Arrow
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Whitepapers IND Readiness Checklist: Assess Your FDA Submission Risk

May 4, 2026

IND Readiness Diagnostic: 12 Questions Sponsors Should Answer Before Submitting

A Practical Framework to Assess IND Readiness Before Filing Identify gaps early. Reduce FDA risk. Strengthen your submission strategy. Preparing for an Investigational New Drug (IND) submission...

Case Study Reducing Patient Burden While Maintaining High-Frequency  Monitoring in a Hemophilia Gene  Therapy Trial

April 20, 2026

Reducing Patient Burden While Maintaining High-Frequency Monitoring in a Hemoph...

Balancing rigorous clinical oversight with patient accessibility is critical in complex gene therapy trials. Intensive early-phase monitoring and complex protocols can place significant burden on...

Case Study Ensure Launch Readiness—Even on the Tightest Timelines

March 30, 2026

Ensure Launch Readiness, Even on the Tightest Timelines

Expediting Promotional Review to Deliver 60+ Materials in Just 4 Weeks When timelines are compressed and stakes are high, promotional review processes can quickly become a bottleneck. This case study...

Previous Resource Arrow Next Resource Arrow
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Previous Webinar Arrow Next Webinar Arrow